# A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients

Source: https://onco.cc/trials/nct06682572/  
OnCo record `nct06682572` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Avutometinib (VS-6766) + Defactinib (VS-6063) in ovarian cancer, run by Verastem, Inc., active and no longer recruiting.

## Summary

A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients is a phase 2 interventional study registered as NCT06682572 by Verastem, Inc., with 16 participants enrolled, started 2024-10-30 and due to reach its primary completion in 2025-12. Interventions recorded: Avutometinib (VS-6766) + Defactinib (VS-6063).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06682572
- Phase: 2
- Setting: A Phase 2 Study of Avutometinib (VS-6766, a Dual RAF/MEK Inhibitor) In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Japanese Patients
- Sponsor: Verastem, Inc.
- Enrolled: 16

## Sources

- ClinicalTrials.gov NCT06682572: https://clinicaltrials.gov/study/NCT06682572

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- companies: [Verastem Oncology](https://onco.cc/companies/verastem/)

---
JSON: https://onco.cc/api/v1/entities/nct06682572.json